PURPOSE: The association between female reproductive factors and glioma risk is unclear, but most published studies have been limited by small sample size. We conducted a pooled multisite study of pre- and postmenopausal women, investigating the effect of female reproductive factors, including hormonal medications. METHODS: Unconditional logistic regression was used to calculate odds ratios (ORs) and 95 % confidence intervals (95 % CIs) assessing the effects of female reproductive factors and female hormonal medications in glioma cases and unrelated controls. RESULTS: Menarche over the age of 15 as compared to under 12 was associated with a statistically significant risk for glioma (OR 2.00, 95 % CI 1.47-2.71). Use of oral contraceptive pills (OCP) was inversely associated with risk of glioma (OR 0.61, 95 % CI 0.50-0.74), and there was an inverse trend with longer duration of OCP use (p for trend <0.0001). Use of hormone replacement therapy (HRT) was also inversely associated with risk of glioma (OR 0.55, 95 % CI 0.44-0.68), and there was an inverse trend with longer duration of use (p for trend <0.0001). Compared to those reporting neither OCP use nor HRT use, those who reported using both were less likely to have a diagnosis of glioma (OR 0.34, 95 % CI 0.24-0.48). CONCLUSIONS: Female reproductive hormones may decrease the risk for glioma. The association appears to be strongest with greater length of use and use of both HRT and OCP.
PURPOSE: The association between female reproductive factors and glioma risk is unclear, but most published studies have been limited by small sample size. We conducted a pooled multisite study of pre- and postmenopausal women, investigating the effect of female reproductive factors, including hormonal medications. METHODS: Unconditional logistic regression was used to calculate odds ratios (ORs) and 95 % confidence intervals (95 % CIs) assessing the effects of female reproductive factors and female hormonal medications in glioma cases and unrelated controls. RESULTS: Menarche over the age of 15 as compared to under 12 was associated with a statistically significant risk for glioma (OR 2.00, 95 % CI 1.47-2.71). Use of oral contraceptive pills (OCP) was inversely associated with risk of glioma (OR 0.61, 95 % CI 0.50-0.74), and there was an inverse trend with longer duration of OCP use (p for trend <0.0001). Use of hormone replacement therapy (HRT) was also inversely associated with risk of glioma (OR 0.55, 95 % CI 0.44-0.68), and there was an inverse trend with longer duration of use (p for trend <0.0001). Compared to those reporting neither OCP use nor HRT use, those who reported using both were less likely to have a diagnosis of glioma (OR 0.34, 95 % CI 0.24-0.48). CONCLUSIONS: Female reproductive hormones may decrease the risk for glioma. The association appears to be strongest with greater length of use and use of both HRT and OCP.
Authors: J A Girón-González; F J Moral; J Elvira; D García-Gil; F Guerrero; I Gavilán; L Escobar Journal: Eur J Endocrinol Date: 2000-07 Impact factor: 6.664
Authors: Judith Schwartzbaum; Fredrik Jonsson; Anders Ahlbom; Susan Preston-Martin; Stefan Lönn; Karin C Söderberg; Maria Feychting Journal: Int J Cancer Date: 2003-09-01 Impact factor: 7.396
Authors: Rebecca B Little; L Burt Nabors; Jeffrey J Olson; Zachary J Thompson; Carrie M Rozmeski; Renato V LaRocca; Peter A Forsyth; Reid C Thompson; Robert A Oster; Sajeel A Chowdhary; Kathleen M Egan Journal: Cancer Causes Control Date: 2017-03-04 Impact factor: 2.506
Authors: Kathleen M Egan; Youngchul Kim; Noemi Bender; James M Hodge; Anna E Coghill; Stephanie A Smith-Warner; Dana E Rollison; Lauren R Teras; Tom K Grimsrud; Tim Waterboer Journal: Sci Rep Date: 2021-05-05 Impact factor: 4.379
Authors: Noah C Peeri; Jordan H Creed; Gabriella M Anic; Reid C Thompson; Jeffrey J Olson; Renato V LaRocca; Sajeel A Chowdhary; John D Brockman; Travis A Gerke; L Burton Nabors; Kathleen M Egan Journal: Cancer Epidemiol Date: 2018-05-25 Impact factor: 2.984